Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases. 

The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation. 

“Partnering with ten23 health strengthens our ability to accelerate the development of our pipeline while maintaining the highest standards of quality,” said Dr Ellen Donnelly, CEO at Neumirna Therapeutics.  

“Their proven track record and expertise support our vision of bringing novel therapies to patients in need. Together, we are taking a decisive step forward in advancing healthcare innovation.”  

“We are honoured to collaborate with Neumirna Therapeutics and support their mission to address critical medical needs through innovative healthcare solutions,” said Dr Susanne Jörg, COO of ten23 health.  

“Our expertise and ongoing research in drug product development, manufacturing, and testing of oligonucleotide therapies, including RNA, align seamlessly with Neumirna’s commitment to delivering life-changing therapies. 

“We share a common goal of improving patient care and look forward to advancing this program effectively and efficiently.”  

There is growing momentum for RNA and oligonucleotide-based therapies, particularly in areas with limited treatment options, such as chronic neurological diseases. Neumirna and ten23 health aim to collaborate to enable faster and more robust advancement of complex therapies, with the ultimate goal of commercialisation. 

Bruno Quinney, Content Team, DDW